The plasma levels of activated thrombin activatable fibrinolysis inhibitor and thrombomodulin in Behcet Disease and their association with thrombosis
Küçük Resim Yok
Tarih
2010
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Pergamon-Elsevier Science Ltd
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Objective: To investigate the plasma levels of activated thrombin activatable fibrinolysis inhibitor (aTAFI) and thrombomodulin (TM) in Behcet disease (BD) and their relationship with thrombosis. Methods: Plasma aTAFI and TM levels were measured by ELISA in 89 patients with BD (18 having venous thrombosis) and in 86 healthy controls. Results: Compared with healthy controls, the BD group had significantly lower levels of aTAFI (13.49 +/- 8.88 mu g/ml vs. 26.76 +/- 11.57 mu g/ml, p<0.0001) and significantly higher levels of TM (3.26 +/- 1.85 ng/ml vs. 2.6 +/- 0.69 ng/ml, p=0.0003). Neither aTAFI, nor TM levels differed significantly between BD patients with and without thrombosis (p>0.05). Despite a tendency to positive correlation (r=0.37, p=0.0004) between plasma levels of aTAFI and TM in healthy controls, there was a tendency for negative correlation (r=-0.51, p<0.0001) between these two parameters in BD patients. Conclusion: The plasma aTAFI and TM levels do not seem to be related with the presence of thrombosis observed in BD. Increased plasma TM levels in BD may simply reflect endothelial cell activation and dysfunction. (C) 2010 Elsevier Ltd. All rights reserved.
Açıklama
Anahtar Kelimeler
Activated thrombin activatable fibrinolysis inhibitor, Behcet disease, Thrombomodulin, Thrombosis
Kaynak
Thrombosis Research
WoS Q Değeri
Q2
Scopus Q Değeri
Cilt
126
Sayı
3
